tiprankstipranks
Purple Biotech Secures $2.8 Million for Oncology Advancements
Company Announcements

Purple Biotech Secures $2.8 Million for Oncology Advancements

Purple Biotech (PPBT) has released an update.

Pick the best stocks and maximize your portfolio:

Purple Biotech has successfully closed a $2.8 million registered direct offering of American Depositary Shares, with H.C. Wainwright & Co. acting as the exclusive placement agent. The funds will be used to advance the development of their oncology therapeutic candidates and support general corporate activities. Investors interested in biotech innovations and oncology therapies might find opportunities with Purple Biotech’s continued progress in overcoming tumor immune evasion and drug resistance.

For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskPurple Biotech Advances Oncology Drugs with New Funding
TipRanks Auto-Generated NewsdeskPurple Biotech Signs Securities Purchase Agreement
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App